NCT05601739

Brief Summary

This study aims to show the association between the Interleukin-1β (rs 1143627 T/C) gene polymorphism and the patient's pain level, radiological features, functional disability, and spinal flexibility.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
94

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 8, 2019

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 10, 2019

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 3, 2020

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

July 31, 2022

Completed
3 months until next milestone

First Posted

Study publicly available on registry

November 1, 2022

Completed
Last Updated

November 1, 2022

Status Verified

July 1, 2022

Enrollment Period

7 months

First QC Date

July 31, 2022

Last Update Submit

October 31, 2022

Conditions

Keywords

lumbar disc degenerationpolymorphisminterleukin 1 betalow back pain

Outcome Measures

Primary Outcomes (5)

  • Genotyping - Interleukin-1β (rs 1143627 T/C) gene polymorphism

    Genotype analysis of interleukin-1β variation was analyzed with Real-Time PCR (polymerase chain reaction) using Applied bioscience 7500 Fast-Real Time PCR machine (Applied Biosystem, Foster City, California, USA). For this analysis, we use Taq primer assay which had rs number 1143627 (Thermo Fisher Scientific, Waltham, California, USA). Reverse and forward primer sequences were used defining used for possible mutations in target variations

    baseline

  • Visual Analog Scale - Pain Assessment

    Visual Analog Scale (VAS) was used to assess the pain severity of the patients. According to VAS, for pain intensity, it is generally rated as "no pain" 0 points and "moderate pain"5, worst pain imaginable" as 10 points (100 mm scale). They were asked to mark their average pain levels by considering one week. The pain level was questioned separately during resting and activity.

    baseline

  • Oswestry Disability Index - Functional Disability

    The functional level assessment was evaluated using the Oswestry Disability Index (ODI). This scale is preferred to measure the performance of the activities necessary for daily living and to define their limitations. In this scale, consist of 10 sections are included about pain level, inactivity daily living, heavy lifting, walking, sitting, standing, sleeping, sexual life, social life and travelling. There are 6 options in each question, and the patient is asked to choose the expression of his condition.

    baseline

  • The Range of Motion of the lumbar spine

    Physiotherapist will measure the Range of Motion of the lumbar spine by using digital goniometer

    baseline

  • Modified Schober Test - Lumbar Spine Flexibility

    Physiotherapist will measure. The posterior interval between both spina iliaca was marked for measurement. After determining 10 cm above and 5 cm below the marked area, the patient was asked to perform trunk flexion while standing. The difference between the initial value and is noted in cm. The difference of 0-5 cm in the test shows that the flexion flexibility decreases, and the difference over 10 cm shows that the flexibility increases. Values between 5-10 cm are considered normal.

    baseline

Secondary Outcomes (2)

  • Pfirrmann's grading - Total Disc Degenerative Disc Score

    baseline

  • McNab's disc classification - Disc displacements

    baseline

Study Arms (2)

Lumbar degenerative disc disease

The case group was made of 50 patients, 24 women (48%) and 26 men (52%) with several clinical symptoms suggestive of LDD and the condition confirmed by MRI.

Healthy

The control group was made of 44 healthy volunteers.

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

The study was conducted between April and November 2019. This is a two-centre study undertaken at Yeditepe University Hospital's Department of Neurosurgery and the Yeditepe Institute of Health Sciences Department of Molecular Medicine. One of the analytical research approaches used was a case/control study.

You may qualify if:

  • Patients with chronic low back pain (over 3 months
  • Aged 18-60 years old
  • With magnetic resonance imaging (MRI) evidencing LDD with Pfirrmann classification

You may not qualify if:

  • Cauda equina syndrome
  • Lumbar spinal stenosis
  • Spinal deformities (scoliosis, kyphosis, spondylolisthesis)
  • Vertebral fractures
  • Inflammatory rheumatic diseases
  • Diabetic neuropathy
  • Pregnancy
  • Drug and alcohol dependence
  • Psychiatric illness
  • Oncologic diseases
  • Who refuse to sign the consent form and donate a blood sample for analysis of genomic DNA.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yeditepe University

Istanbul, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITH DNA

Interleukin 1-β (rs 1143627 T/C) Gene Polymorphism

MeSH Terms

Conditions

Intervertebral Disc DegenerationLow Back PainInflammation

Condition Hierarchy (Ancestors)

Spinal DiseasesBone DiseasesMusculoskeletal DiseasesBack PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPathologic Processes

Study Officials

  • Dilek Ünsal, M.S.c

    Yeditepe University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 31, 2022

First Posted

November 1, 2022

Study Start

April 8, 2019

Primary Completion

November 10, 2019

Study Completion

April 3, 2020

Last Updated

November 1, 2022

Record last verified: 2022-07

Data Sharing

IPD Sharing
Will not share

Locations